Drugs / HLX79
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07038382 | Aug 2025 → Jan 2027 expected | lupus nephritis, membranous glomerulonephritis | Shanghai Henlius Biotech | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-04-02 | Palleon Pharmaceuticals, Inc. | Regulatory Palleon Pharmaceuticals Announces NMPA IND Clearance to Proceed with Phase 2 Clinical Trial of E-602 (HLX79), a First-In-Class Treatment for Autoimmune Diseases palleonpharma.com ↗
With this clearance, Henlius will initiate the first clinical trial of Palleon’s glyco-immunology platform in autoimmune diseases. |
| 2025-03-25 | Shanghai Henlius Biotech | Regulatory Henlius Announces China’s NMPA Approval of Phase 2 Clinical Trial for HLX79 Plus HANLIKANG in Active Glomerulonephritis henlius.com ↗
the National Medical Products Administration (NMPA) has approved the investigational new drug (IND) application for a phase 2 clinical trial |
All press releases naming this drug 6 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HLX79 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07038382 ↗ |
| Modality | Protein / enzyme biologic | “HLX79 (Human Sialidase Fusion Protein)” NCT07038382 ↗ |